Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2017-10-25 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the third quarter (Q3) and the first nine months (Jan-Sep) of 2017. It contains detailed financial statements, business reviews, CEO statements, and financial summaries. It is not an announcement of a report (RPA) because it contains the actual substantive financial data and analysis. It is not a full Annual Report (10-K) as it focuses on an interim period. Therefore, it is classified as an Interim/Quarterly Report. Q3 2017
2017-10-25 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release (PRESSMEDDELANDE) dated August 31, 2017, announcing a change in the total number of shares and votes in the company due to the conversion of C-shares (issued for incentive programs) into common shares. This directly relates to changes in the company's capital structure and share count. This fits the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not a general earnings release (ER), a full annual report (10-K), or a dividend notice (DIV).
2017-08-31 Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly details a change in the total number of shares and votes due to the issuance and subsequent conversion of Class C shares into common shares, effective August 31, 2017. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). The document is not a general announcement of a report (RPA) or a miscellaneous filing (RNS), but a specific disclosure about share capital.
2017-08-31 English
The board of directors exercises authorization for repurchase of shares to secure the company’s commitments under incentive programme
Transaction in Own Shares Classification · 98% confidence The document explicitly discusses the board of directors exercising authorization for the 'repurchase of shares' to fulfill commitments under an incentive program. It details the resolution to repurchase class C shares and the subsequent conversion to common shares. This action directly relates to the company buying back or selling its own shares, which aligns perfectly with the definition of 'Transaction in Own Shares' (POS). The document is short and appears to be an official announcement of this specific corporate action, not a comprehensive annual or interim report.
2017-07-19 English
Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated July 19, 2017, titled 'Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram' (The Board exercises buyback authorization to secure the company's commitments under the incentive program). The core content details the board's decision to repurchase C-shares using an authorization granted at the AGM to fulfill obligations under an incentive program. This action directly relates to the company buying back or managing its own shares. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase/issuance. It is not a general financing update (CAP) as it is specific to fulfilling an existing incentive plan via repurchase, nor is it a general capital change (SHA).
2017-07-19 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport APR-JUNI 2017' (Interim Report April-June 2017) and contains comprehensive financial statements, management commentary, and operational highlights for the second quarter and first half of 2017. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). Q2 2017
2017-07-19 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.